Literature DB >> 28929220

[Pathogenesis and genetics of osteosarcoma : Current concepts and developments].

D Baumhoer1.   

Abstract

Osteosarcomas are genetically complex tumours for which the cell of origin and the molecular pathogenesis are still poorly understood. Despite intensive multimodal treatment protocols only two thirds of patients currently survive the disease which is at least partly due to the early occurring chromosomal instability resulting in marked inter- and intratumoral heterogeneity. This review article outlines the current state of osteosarcoma research with a particular focus on exome- and genome-wide sequencing analyses and potential impacts on new therapeutic opportunities.

Entities:  

Keywords:  BRCAness; Checkpoint inhibitors; Chromothripsis; Copy number alterations; Osteosarcoma

Mesh:

Year:  2018        PMID: 28929220     DOI: 10.1007/s00292-017-0365-y

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  28 in total

Review 1.  Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors:  Hung T Khong; Nicholas P Restifo
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

2.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

Review 3.  RECQ DNA helicases and osteosarcoma.

Authors:  Linchao Lu; Weidong Jin; Hao Liu; Lisa L Wang
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

4.  Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma.

Authors:  Jan Smida; Daniel Baumhoer; Michael Rosemann; Axel Walch; Stefan Bielack; Christopher Poremba; Klaus Remberger; Eberhard Korsching; Wolfram Scheurlen; Christian Dierkes; Stefan Burdach; Gernot Jundt; Michael J Atkinson; Michaela Nathrath
Journal:  Clin Cancer Res       Date:  2010-07-07       Impact factor: 12.531

5.  Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.

Authors:  Tatiana Popova; Elodie Manié; Guillaume Rieunier; Virginie Caux-Moncoutier; Carole Tirapo; Thierry Dubois; Olivier Delattre; Brigitte Sigal-Zafrani; Marc Bollet; Michel Longy; Claude Houdayer; Xavier Sastre-Garau; Anne Vincent-Salomon; Dominique Stoppa-Lyonnet; Marc-Henri Stern
Journal:  Cancer Res       Date:  2012-08-29       Impact factor: 12.701

6.  Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.

Authors:  Jennifer A Perry; Adam Kiezun; Peter Tonzi; Eliezer M Van Allen; Scott L Carter; Sylvan C Baca; Glenn S Cowley; Ami S Bhatt; Esther Rheinbay; Chandra Sekhar Pedamallu; Elena Helman; Amaro Taylor-Weiner; Aaron McKenna; David S DeLuca; Michael S Lawrence; Lauren Ambrogio; Carrie Sougnez; Andrey Sivachenko; Loren D Walensky; Nikhil Wagle; Jaume Mora; Carmen de Torres; Cinzia Lavarino; Simone Dos Santos Aguiar; Jose Andres Yunes; Silvia Regina Brandalise; Gabriela Elisa Mercado-Celis; Jorge Melendez-Zajgla; Rocío Cárdenas-Cardós; Liliana Velasco-Hidalgo; Charles W M Roberts; Levi A Garraway; Carlos Rodriguez-Galindo; Stacey B Gabriel; Eric S Lander; Todd R Golub; Stuart H Orkin; Gad Getz; Katherine A Janeway
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

7.  Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.

Authors:  V Abkevich; K M Timms; B T Hennessy; J Potter; M S Carey; L A Meyer; K Smith-McCune; R Broaddus; K H Lu; J Chen; T V Tran; D Williams; D Iliev; S Jammulapati; L M FitzGerald; T Krivak; J A DeLoia; A Gutin; G B Mills; J S Lanchbury
Journal:  Br J Cancer       Date:  2012-10-09       Impact factor: 7.640

8.  Massive genomic rearrangement acquired in a single catastrophic event during cancer development.

Authors:  Philip J Stephens; Chris D Greenman; Beiyuan Fu; Fengtang Yang; Graham R Bignell; Laura J Mudie; Erin D Pleasance; King Wai Lau; David Beare; Lucy A Stebbings; Stuart McLaren; Meng-Lay Lin; David J McBride; Ignacio Varela; Serena Nik-Zainal; Catherine Leroy; Mingming Jia; Andrew Menzies; Adam P Butler; Jon W Teague; Michael A Quail; John Burton; Harold Swerdlow; Nigel P Carter; Laura A Morsberger; Christine Iacobuzio-Donahue; George A Follows; Anthony R Green; Adrienne M Flanagan; Michael R Stratton; P Andrew Futreal; Peter J Campbell
Journal:  Cell       Date:  2011-01-07       Impact factor: 41.582

9.  TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome.

Authors:  Sebastian Ribi; Daniel Baumhoer; Kristy Lee; Audrey S M Teo; Babita Madan; Kang Zhang; Wendy K Kohlmann; Fei Yao; Wah Heng Lee; Qiangze Hoi; Shaojiang Cai; Xing Yi Woo; Patrick Tan; Gernot Jundt; Jan Smida; Michaela Nathrath; Wing-Kin Sung; Joshua D Schiffman; David M Virshup; Axel M Hillmer
Journal:  Oncotarget       Date:  2015-04-10

10.  Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.

Authors:  Florian Engert; Michal Kovac; Daniel Baumhoer; Michaela Nathrath; Simone Fulda
Journal:  Oncotarget       Date:  2017-07-25
View more
  2 in total

1.  Expression and role of microRNA-1271 in the pathogenesis of osteosarcoma.

Authors:  Gongbiao Lu; Lin Du; Yi Guo; Baohua Xing; Jishou Lu; Yanchun Wei
Journal:  Exp Ther Med       Date:  2017-12-15       Impact factor: 2.447

2.  Effectiveness of electroacupuncture for pain after osteosarcoma post surgery: A study protocol of systematic review of randomized controlled trial.

Authors:  Chi He; Qing-Xi Tang; Ying-Xia Li; Kai He; Zhi-Ling Hou
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.